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ACTB encodes b-actin, an abundant cytoskeletal housekeeping protein. In humans, postulated gain-of-function missense mutations
cause Baraitser-Winter syndrome (BRWS), characterized by intellectual disability, cortical malformations, coloboma, sensorineural deaf-
ness, and typical facial features. To date, the consequences of loss-of-function ACTB mutations have not been proven conclusively. We
describe heterozygous ACTB deletions and nonsense and frameshift mutations in 33 individuals with developmental delay, apparent
intellectual disability, increased frequency of internal organ malformations (including those of the heart and the renal tract), growth
retardation, and a recognizable facial gestalt (interrupted wavy eyebrows, dense eyelashes, wide nose, wide mouth, and a prominent
chin) that is distinct from characteristics of individuals with BRWS. Strikingly, this spectrum overlaps with that of several chromatin-
remodeling developmental disorders. In wild-type mouse embryos, b-actin expression was prominent in the kidney, heart, and brain.
ACTB mRNA expression levels in lymphoblastic lines and fibroblasts derived from affected individuals were decreased in comparison
to those in control cells. Fibroblasts derived from an affected individual and ACTB siRNA knockdown in wild-type fibroblasts showed
altered cell shape andmigration, consistent with known roles of cytoplasmic b-actin.We also demonstrate that ACTB haploinsufficiency
leads to reduced cell proliferation, altered expression of cell-cycle genes, and decreased amounts of nuclear, but not cytoplasmic, b-actin.
In conclusion, we show that heterozygous loss-of-function ACTB mutations cause a distinct pleiotropic malformation syndrome with
intellectual disability. Our biological studies suggest that a critically reduced amount of this protein alters cell shape, migration, prolif-
eration, and gene expression to the detriment of brain, heart, and kidney development.Developmental disorders (DDs) are thought to affect 2%–
5% of individuals and are genetically heterogeneous.1
They range from isolated internal organ malformations
and intellectual disability to complex syndromic presenta-
tions. In developed economies, congenital malformations
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Figure 1. ACTB Loss-of-Function Mutations Result in Reduced Expression
(A) Discovery cohort—a representation of chromosome 7 with four small 7p22.1 deletions identified in the discovery cohort. The red
bars represent the extent of genomic deletions, and the associated family number is linked to Table 1.
(B) Validation cohort—the 19 small 7p22.1 deletions identified in the validation cohort. The red bars represent the extent of genomic
deletions, and the associated family number is linked to Table 1.
(C) Intragenic ACTB mutations—the location of the known protein-coding genes on 7p22.1 are shown in blue boxes. ACTB is high-
lighted by two flanking dashed blue lines. The lower panel shows the exon structure of ACTB. The boxes represent the ACTB exons,
and the blue arrows denote the introns. Note that ACTB is transcribed from the reverse strand. The filled (blue) and unfilled sections
of the exons denote translated and untranslated regions of the gene, respectively. Location of mutations in the three affected individuals
is shown with red arrows—one with a small frameshift deletion (XXIV: p.Ser368LeufsTer13), one with a nonsense mutation (XXV:
p.Lys373Ter) and one with de novo frameshift mutation (XXVI: p.Leu110ArgfsTer10). The transcript ID is NM_001101.3.
(D) ACTB loss-of-function mutations result in reduced gene expression—quantitative real-time polymerase chain reaction (qRT-PCR)
analysis of ACTB transcript levels relative to GAPDH in fibroblasts, LCL and blood samples (sample P1 is from IVa, P2 is from XI, P3
is from II, and P4 is fromXXII). Cells were collected by centrifugation, and total RNAswere extracted with the RNeasyMini kit (QIAGEN)
according to the manufacturer’s protocol. The qRT-PCR reactions were performed on a Bio-Rad CFX394 Real-Time system (Bio-Rad) with
Power SYBR Green PCR Master mix (Applied Biosystems). The expression of each target gene was evaluated via a relative quantification
approach (-DCT method), and GAPDH was used as the internal reference for human genes.individuals who underwent clinical array comparative
genomic hybridization for suspected genetic DDs at our
center, we identified five individuals from four families
with 7p22.1 deletions (Figure 1A; Table S1) and an overlap-
ping phenotype (families I–IV in Table 1; Figure 2A). ACTB
[MIM: 102630] was the only gene common to all four de-1022 The American Journal of Human Genetics 101, 1021–1033, Decletions, leading us to hypothesize that ACTB haploinsuffi-
ciency leads to a distinct clinical syndrome.
We ascertained 26 additional individuals from 19 fam-
ilies with likely or definitely pathogenic 7p22.1 deletions
that were <3Mb and encompassed ACTB (Figure 1B; Table
S1). Next, we interrogated data from 4,293 trios in theember 7, 2017
Figure 2. ACTB Loss-of-Function Mutations Result in a Recognizable Phenotype
(A) Facial gestalt and physical anomalies with ACTB loss-of-function mutations—the facial features of a number of individuals who had
7p22.1 deletions or point mutations (marked with *) in ACTB were remarkably similar to each other; they had wavy interrupted eye-
brows, dense eyelashes, a wide nose, a widemouth, and a prominent chin. Several affected individuals in this cohort demonstrated over-
lapping toes, small nails, and spinal anomalies such as sacral dimples.
(B) Immunohistochemistry of embryonic day 14 mice. The top row shows b-actin immunostaining (brown) in neurons in the brain
(neocortex), epithelia of kidney tubules (S-shaped body), and the heart (endocardium and cardiac outflow). The bottom row shows sec-
tions with primary antibody omitted so that the specificity of the above signals is shown. Whole embryos at day 14 (E14) were fixed in
4% paraformaldehyde and embedded in paraffin. Sections of 5 mmwere cut and mounted on polylysine-coated glass slides. Endogenous
(legend continued on next page)
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Deciphering Developmental Disorders study1 for de novo
nonsense or frameshift variants in all known protein-cod-
ing genes on chromosome 7p22.1. We identified two
ACTB point mutations, c.1097dupG; p.Ser368LeufsTer13
and c.1117A>T; p.Lys373Ter, in two children (NM_
001101.3; ENST00000331789) (Figures 1C; Table S1).
Finally, we identified another individual with a
c.329delT; p.Leu110ArgfsTer10 ACTB point mutation in
the CAUSES Study by using the analytical pipeline
described previously.8 The procedures followed were in
accordance with the ethical standards of the responsible
committee on human experimentation (institutional and
national), and proper informed consent was obtained.
Multiple lines of evidence establish ACTB loss-of-func-
tion mutations as a cause of a pleiotropic clinical syn-
drome. First, of the genes on human chromosomal region
7p22.1, ACTB is the only one with a high-probability loss-
of-function intolerance (pLI) score9 and low residual varia-
tion intolerance score (RVIS)10 as well as a low haploinsuf-
ficiency index (HI)11 (Table S2). Second, it was the only
gene deleted within the minimum critical region in both
the discovery and validation cohorts of individuals with
7p22.1 deletions. Importantly, we also identified three in-
dividual with ACTB point mutations that, like the dele-
tions, are expected to produce a heterozygous null ACTB
genotype. Third, mutations, including all point mutations,
were proven to have arisen de novo in 12 individuals. Bio-
logical parentage was proven in the three individuals
who were identified via exome sequencing. In
all multiplex families, the deletions segregated with the
phenotype. Fourth, the striking phenotypic convergence
in a large cohort ascertained on the basis of genotyping
followed by reverse phenotyping12 rules out possibility of
a chance association. Collectively, in this cohort of 33 in-
dividuals from 25 unrelated families we observed a high
frequency of developmental delay, apparent intellectual
disability, internal organ malformations (affecting heart,
kidneys, spine, and palate, among others), growth retarda-
tion, and facial dysmorphism (interrupted eyebrows, dense
eyelashes, wide nose, wide mouth, and a prominent chin)
(Figure 2A; Table 1).
We performed qRT-PCR and measured ACTB mRNA
expression in fibroblasts, lymphoblastic cell lines (LCLs),
and fresh blood. Expression levels in affected individual-
derived cells were consistently lower than in control sam-
ples (Figure 1D). Similar findings have been reported in
Actbþ/ mice13 and in immortalized lymphocytes derived
from one individual with a 7p22.1 microdeletion.14
Next, we analyzed b-actin expression in embryonic day
14 mice, a stage when organogenesis is ongoing; this stage
is anatomically similar to the late first trimester of human
gestation. b-actin was prominent in organs affected by theperoxidase was quenched by incubation with hydrogen peroxide (0.3
sodium citrate (pH 6) for antigen exposure. Rabbit anti-b-actin (1:250
Goat anti-rabbit (1:200) was applied for 1 hr at room temperature and
(Vector) and hematoxylin counter-stain (scale bar: 50 mm).
1024 The American Journal of Human Genetics 101, 1021–1033, Decsyndrome: cortical neurons and choroid plexus epithelia
in the brain; differentiating tubules of the metanephric
kidney; and the epicardium, endocardium, and muscle in
the outflow tract of the heart (Figures 2B). Notably, it was
not expressed uniformly in all embryonic cell types, even
from within an organ.
b-actin is essential for a number of cytoplasmic functions,
such as regulation of cell shape and migration.13,15,16 We
performed an immunoblot and quantified the amount of
b-actin in the cytoplasmic protein fraction of affected indi-
vidual cells, but no consistent differences in b-actin expres-
sionwereobserved inaffected individual-derived cells versus
controls (Figure 3A). However, affected individual-derived
fibroblasts were significantly more circular than controls,
although there was no alteration in the average cell size
(Figure S1). Their migration was also severely impaired in
comparison to that of control fibroblasts (Figure 3C). Impor-
tantly, silencing-RNA (siRNA)-mediated downregulation of
ACTB in control fibroblasts (Figure S2) induced a similar
increase in circularity (Figure 3B) and migration defects
(Figure 3C), proving that the changes in cells with a 7p22.1
deletion were primarily due to ACTB haploinsufficiency.
In the nucleus b-actin regulates gene expression, cell
division, and proliferation.17,18 Interestingly, in contrast
to the cytoplasmic fraction, the nuclear protein fraction
showed a reduced amount of b-actin in cells derived from
affected individuals (Figure 4A). Interference with nuclear
b-actin function directly correlates with levels of transcrip-
tion and cell proliferation.19 Accordingly, we found
significantly decreased cellular proliferation in affected
individual-derived cells (Figures 4B and 4C). We examined
expression of cell-cycle genes by using RNA-Seq on sam-
ples derived from two controls and two LCLs from affected
individuals (Table S3). In cells from affected individuals,
we detected 11-fold increased expression of CCND1
[MIM: 168461], a key gene that encodes cyclin D1, which
should be downregulated for cells to transition from G1
into the S phase (Figure 4C).20 This is consistent with the
previous observation that b-actin inhibition leads to arrest
in the G1 phase.21 Furthermore, the expression levels of
several S- and G2-phase genes were lower in LCLs from
affected individuals than in control LCLs (Figure 4C).
Although chromosome 7p22.1 deletions have been
described in a small number of affected individuals previ-
ously, ACTB has not been conclusively proven to be
the underlying gene responsible for the phenotype.15 We
have now described numerous affected families, suggest-
ing that the syndrome caused by loss-of-function ACTB
mutations might have been under-recognized. Variation
in the phenotype could be due to differences in the sizes
of deletion causing loss of additional genes or long-range
regulatory dysfunction or due to genetic background or% solution in PBS). Embryos were heated at 95C for 5 minutes in
, Abcam ab8227) was applied to tissue sections over night at 4C.
revealed with the ABC Elite kit (Vector) followed by DAB staining
ember 7, 2017
Table 1. Clinical Features of Individuals with Deletions, Stop-Gained, or Frameshift Mutations Involving ACTB
Case ID Inheritance Gender
Age
(Years)
Prenatal and
Neonatal History
PN Growth
Retardation Microcephaly
Motor
Delay
Speech
Delay DD/ ID
Behavioral, Psychiatric,
and Neurological Features
Malformations and
Physical Anomalies
Additional
Comments
Discovery Cohort
I DN M 4 SGA and feeding
difficulties
Y N Y Y mod possible absence and
focal seizures
VSD with tortuous aortic
arch, horseshoe kidney,
cryptorchidism, BL
inguinal hernia, deep
sacral dimple and BL
single palmar creases
early-onset
hypothyroidism,
limitation of joint
mobility and cutis
marmorata
II DN M 7 SGA and feeding
difficulties
Y N Y Y mild sociable, empathetic,
hand flapping tendency
and attention deficit
Rt pelvic kidney, Rt
inguinal hernia and
scoliosis.
GOR, asthma and
allergies.
III DN M 7 SGA, polycythaemia,
jaundice and
hypoglycaemia.
Congenital CMV
infection
Y Y N Y Mild attention deficit, echolalia
and tantrums.
inguinal hernia,
cryptorchidism,
proximally placed
second toes and
microcornea.
perineal and scalp
abscesses, recurrent
chest and ear
infections, allergies
and nephrotic
syndrome.
IVa Mat F 32 SGA Y N Y Y mod empathetic personality. scoliosis glaucoma, asthma,
and eczema
IVb U F 68 U U U U U mild U horseshoe kidney with
multiple cysts
hiatus hernia
Validation Cohort
V DN F 13 SGA and feeding
difficulties
Y N Y Y mod sociable personality, mild
ventriculomegaly, and
multifocal small T2
hyperintensitites in the
cerebral white matter
VSD, PDA, BL 5th finger
clinodactyly, BL 2-3 &
Lt 3-4 toe syndactyly
N
VI U M 20 N Y N N Y mild stress intolerance. short and broad uvula,
broad halluces, short
distal phalanx of finger
and toes, small nails,
and 5th finger
clinodactyly.
frequent otisis media,
GH deficiency and
limitation of joint
mobility
VII DN F 12 SGA, hypotonia and
feeding difficulties
Y Y Y Y mod emotional problems
and hypotonia
tricuspid valve dysplasia,
2-3-4 fingers and 2-3 toes
syndactyly
BL severe SNHL and
dorsal hypertrichosis
VIII DN M 7 SGA, hypotonia and
feeding difficulties
Y N Y Y sev Thin CC, septum
pellucidum cyst,
megacisterna magna,
mild ventricular dilation
and subependymal
heterotopia
BL CLAP, VSD, Lt extra
nipple, hypospadias, UL
cryptorchidism and sacral
dimple
cutis marmorata;
additional de novo
1.65 Mb loss
7:6243891-7889083
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Table 1. Continued
Case ID Inheritance Gender
Age
(Years)
Prenatal and
Neonatal History
PN Growth
Retardation Microcephaly
Motor
Delay
Speech
Delay DD/ ID
Behavioral, Psychiatric,
and Neurological Features
Malformations and
Physical Anomalies
Additional
Comments
IX DN M 6 hypotonia and
feeding difficulties
Y Y Y Y mod cortical and subcortical
atrophy
atrial septal defect and BL
inguinal hernia
GOR
X DN F 0 (fetus) antenatal
ultrasound: cleft
lip and palate,
septum pellucidum
agenesis
NA NA NA NA NA absent septum pellucidum
and hydrocephalus
horseshoe kidney and
non-midline CLAP
N
XI DN M 6 hypotonia and
feeding difficulties
N N Y Y mod sociable personality, ASD,
hypotonia, possible seizures
and periventricular
heterotopias
BL absent thumbs,
bowed radii, shortened
forearms, chordee and
parameatal cyst
GOR and
hypermetropia.
Published Shimojima
et al., 201614 ( #3)
XII U F 21 N N N Y Y Mild sociable personality,
attention deficit,
trichotillomania and
seizures in early childhood
VSD, scoliosis,
clinodactyly, short
thumbs, camptodactyly
fetal finger pads,
tapering finger and
2-3 toe syndactyly
asthma, eczema,
reduced elbow and
shoulder extension,
BL keratoconus and
early Lt posterior
subcapsular cataract
XIII DN F 2 SGA Y Y Y Y mild N supra-valvular aortic
stenosis
N
XIV DN M 20 hypotonia and
feeding difficulties
U U Y Y mod empathetic personality
and ASD.
Pierre Robin sequence,
Dislocated radial heads,
Rt single palm crease,
fetal finger pads, narrow
fingernails, brachydactyly
and toe camptodactyly
marked external
rotation of hips,
HL. Lt Astigmatism.
Thin scalp hair.
Published in
Shimojima et al.,
201614 (#2)
XV DN M 4 months SGA,
polyhydramnion
Y Y NA NA NA hypertonia micropenis, retrognathia,
dysplastic ears
additional paternally
inherited 370 Kb loss
14:27438600-
27806980
XVI U M 38 SGA Y N N Y mild ASD, drooling and seizures. thoracic kyphosis and BL
inguinal hernia
delayed puberty and
recurrent sinusitis
XVIIa mat F 2 hypotonia and
feeding difficulties.
N N Y Y mild hypotonia N chronic respiratory
infections
XVIIb U F 34 N Y Y N Y mild acute psychosis age 10,
attention deficit and
infarction right frontal
cortex
fifth-finger clinodactyly. chronic sinusitis
(Continued on next page)
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Table 1. Continued
Case ID Inheritance Gender
Age
(Years)
Prenatal and
Neonatal History
PN Growth
Retardation Microcephaly
Motor
Delay
Speech
Delay DD/ ID
Behavioral, Psychiatric,
and Neurological Features
Malformations and
Physical Anomalies
Additional
Comments
XVIII DN F 13 SGA N N Y Y mild anxious personality and
pathological demand
avoidance
gap between palate and
posterior wall of pharynx.
recurrent urinary
tract infections
XIXa mat F 7 N N Y N N mod N TAPVD, scoliosis,
tapering digits and fetal
finger pads.
BL HL
XIXb mat F 5 SGA N Y Y Y mild N atrial septal defect, sacro-
coccygeal sinus and
tethering of spinal cord
BL HL
XIXc mat M 2 N N N Y Y mod N VSD, horseshoe kidney,
VUR and hydronephrosis
BL HL and Rt eye
strabismus
XIXd U F 37 N N N N N mild N N N
XXa
twin I
mat F 4 born at 26 week
gestation,
oligohydramnios
and dizygotic
twins; SGA,
hypotonia and
feeding difficulties
Y Y Y Y mod attention deficit, CC
hypoplasia and cortical
atrophy
N both have BL
moderate SNHL
and strabismus;
additional paternally
inherited 1.78Mb
dup 16:88335976-
90111263; Published
in Shimojima et al.,
201614 (#4 & 5)
XXb
twin II
mat F 4 Y Y Y Y mod attention deficit N
XXc U F 27 SGA Y Y Y Y mild Attention deficit N published in
Shimojima et al.,
201614 (mother of
#4 & 5)
XXI pat M 4 feeding difficulties N Y Y Y mod ASD and hypotonia N hypermobile joints;
additional paternally
inherited
16p11.2dup.
XXII U M 11 hypotonia and
feeding difficulties
Y Y Y Y mod affectionate personality,
self-harming tendency, ASD,
hypotonia and gray matter
heterotopia
renal cortical cysts,
congenital diaphragmatic
hernia, scoliosis, fetal
finger pads and
brachydactyly
severe GOR, eczema
and BL mixed HL.
XXIII U M 23 feeding difficulties
and hypoglycemia
N N N Y mod anxious personality and
schizophrenia.
unilateral renal agenesis,
ectopic testis, rectal
stenosis, umbilical hernia,
high palate, kyphosis
and scoliosis
N
(Continued on next page)
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Table 1. Continued
Case ID Inheritance Gender
Age
(Years)
Prenatal and
Neonatal History
PN Growth
Retardation Microcephaly
Motor
Delay
Speech
Delay DD/ ID
Behavioral, Psychiatric,
and Neurological Features
Malformations and
Physical Anomalies
Additional
Comments
Point Mutations
XXIV DN M 12 feeding difficulties Y Y Y N mod hyperactivity and dystonia tracheesophageal fistula,
esophageal atresia,
overlapping toes, short
foot and tapered fingers
and pectus excavatum.
hypertrichosis
XXV DN F 14 feeding difficulties N Y N Y mild N lytic lesions in both
parietal bones suggestive
of congenital parietal
foramina
extra-skin folds on
abdomen and back
XXVI DN M 18 N N N Y Y mild slight social inhibition atrial septal defect and
pectus deformity
BL SNHL, distal
interphalangeal joint
contracture of left 5th
finger, BL knee
flexion contractures,
mild weakness in
ankle plantar flexion;
dihydropyrimidine
dehydrogenase
deficiency due to
compound
heterozygous
pathogenic
mutations in DYPD;
additional
maternally inherited
duplications
(chr10:117216305-
117530316 and
chr10:117616145-
118447670)
This table summarizes the clinical features of individuals in the discovery or validation cohort and point mutations involving ACTB (ASD, autistic spectrum disorder; BL, bilateral; CC, corpus callosum; CLAP, cleft lip and palate;
DD, developmental delay; DN, de novo; HL, hearing loss; F, female; GH, growth hormone; GOR, gastresophageal reflux; ID, intellectual disability; Lt, left; M, male; mat, maternal/mother; mod, moderate; N, no or none
known; NA, not applicable; PDA, patent ductus arteriosus; PN, postnatal; pat, paternal/father; Rt, right; sev, severe; SGA, small for gestational age; SNHL, sensorineural hearing loss; TAPVD, total anomalous pulmonary venous
drainage; U, unknown; VSD, ventricular septal defect; VUR, vesicoureteric reflux; and Y, yes).
1
0
2
8
T
h
e
A
m
e
rica
n
Jo
u
rn
a
l
o
f
H
u
m
a
n
G
e
n
e
tics
1
0
1
,
1
0
2
1
–
1
0
3
3
,
D
e
ce
m
b
er
7
,
2
0
1
7
Figure 3. ACTB Loss-of-Function Mutations Induce Abnormalities of Cellular Morphology and Reduced Migration
(A) Immunoblots of cytoplasmic b-actin. No consistent differences were detected in the cytoplasmic b-actin amounts in the fibroblasts
and LCLs of affected individuals versus controls (sample P1 is from IVa, P2 is from XI, P3 is from II, and P4 is from XXII). Immunoblot-
ting for b-actin was performed on the cytoplasmic protein fraction, and GAPDH was used as a loading control. Protein samples were
isolated using NE-PER nuclear and cytoplasmic extraction reagents (ThermoScientific). 8–10 mg of protein extracts were loaded into
the polyacrylamide gel Bolt 10% Bis-Tris Plus Gels (Invitrogen). The membranes were incubated with specific anti-beta actin (ab8227,
Abcam) and anti-GAPDH (5174S, Cell Signaling) overnight at 4C. After washes, the membranes were incubated with a secondary fluo-
rescently labeled goat anti-rabbit antibody (IRDye 800CW Li-Cor), and signal was developed with an Odyssey CLX imaging machine.
(B) Fibroblast morphology. ACTB-deficient cells were found to be significantly more circular than non-deficient cells. Phalloidin and
DAPI immunostaining was performed in wild-type fibroblasts transfected with 30 nM control siRNA (ON-TARGETplus non-targeting
pool, Fisher) and ACTB siRNA (SMARTpool ON TARGET plus ACTB siRNA, Dharmacon) and affected-individual fibroblasts transfected
with control siRNA. Cells were fixedwith 4% paraformaldehyde for 15minutes at room temperature. After blocking solutionwas washed
out, antibody Texas Red-X Phalloidin (T7471, Life Technologies) was applied for 1 hr at room temperature in the dark. Samples were
stained with DAPI (4083S, Cell Signaling Technology) for 5 min. Representative pictures show marked difference in the morphology
of b-actin-deficient cells (scale bar: 50 mm). Enlargement of cells is shown in the lower panels. Dashed lines show the outline of the
cell boundary. The left bar chart shows that there was no significant difference in the area of each of the cell groups (in mm2) as calculated
with ImageJ software. The right bar chart shows the increased circularity of the ACTB-deficient fibroblasts as calculated with ImageJ
software (n ¼ 4; **p < 0.01). Values of 1 and 0 stand for a perfect circle and a line, respectively. Error bars indicate mean 5 1 SD.
(C) Fibroblast migration. ACTB-deficient cells had impaired migration. A migration assay was performed in wild-type fibroblasts trans-
fected with control siRNA and ACTB siRNA and affected-individual fibroblasts transfected with control siRNA. 96 hr after transfection, a
woundwas generated in the confluentmonolayer of fibroblasts via a p200 pipet tip. Cells were washedwith phosphate-buffered saline so
that any debris created by the wound would be removed. The first image of the wound was taken with a phase-contrast microscope, and
marking the plate under the capture image field created a reference point. Cells were incubated at 37C in a humidified 5% CO2
incubator for 2 days. After the incubation time, a second image was taken. For quantifying the migration of cells, the cells that crossed
into the wound area were counted. Representative pictures show reducedmigration in b-actin-deficient cells (scale bar: 100 mm). The bar
chart shows that the numbers of cells in the central wound area are significantly lower in the b-actin-deficient cells. Data are shown as
the mean of absolute cell numbers at 144 hours from two wells of two independent experiments (n¼ 4; *p< 0.05, **p< 0.01). Error bars
indicate mean5 1 SD.
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Figure 4. ACTB Loss-of-Function Mutations Lead to Reduced Expression of b-actin in the Nucleus, Reduced Cell Proliferation, and
Dysregulation of Cell-Cycle Genes
(A) Immunoblots of nuclear b-actin. Nuclear b-actin amounts in fibroblasts and LCLs from affected individuals were consistently lower
than those of their respective controls (sample P1 is from IVa, P2 is from XI, P3 is from II, and P4 is from XXII). Immunoblotting for
b-actin (ab8227, Abcam) was performed on the nuclear protein fraction with histone 3 (ab1791, Abcam) as a loading control. Visual
inspection of the membranes and their intensity quantification revealed a consistent trend of decreased amounts of nuclear b-actin
in fibroblasts and LCLs from affected individuals versus controls (sample P1 is from IVa, P2 is fromXI, P3 is from II, and P4 is fromXXII).
(B) Fibroblast and LCL proliferation. Proliferation in cells derived from affected individuals was found to be significantly reduced.
Quantification of the number of fibroblasts and LCLs was performed in a 12-well plate. Cells were plated in the presence of their growth
medium and counted with a hemocytometer every 3 days for 9 days. Fibroblasts and LCLs from affected individuals proliferated
significantly slowly in comparison with the control cells. Data are shown as the mean of absolute cell number from three wells of three
independent experiments (n ¼ 3; *p < 0.05, **p < 0.01). Error bars indicate mean5 1 SD.
(C) Expression of cell-cycle genes in LCLs. Cell-cycle genes were dysregulated in LCLs from affected individuals. The abundance of
selected mRNAs in LCLs derived from individuals XI (P2) and XXII (P4) is shown relative to mean amounts in LCLs in two control in-
dividuals; measurements are in FPKM (fragments per kilo base of transcript per million mapped reads). Libraries were prepared for
sequencing with the NEBNext Ultra Directional RNA Library Prep Kit for Illumina (New England Biolabs) according to the manufac-
turer’s instructions. Sequencing of a single 75 bp read was carried out on a NextSeq 500 sequencer (Illumina) according to the manufac-
turer’s protocols. An average of 34.9 million reads was generated per sample. For each sample, the RNA-Seq reads were aligned to the
human reference GRCh37 with Tophat v2.1.0. Cufflinks v2.2.2 was used for assembling the aligned reads against UCSC hg19_refgene
transcripts and for generating the relative expression levels, measured as FPKM, for each transcript within each sample. The expression
of CCND1 is more than 11-fold higher in cells of affected individuals than in controls. The expression of a majority of genes expressed
in S and G2 phase is reduced in cells of affected individuals.environmental effects. Notably, two point mutations in
exon 6 are predicted to escape nonsense-mediated decay,
and one in exon 3 is predicted to cause protein truncation.
Still, it is remarkable that the phenotype of these individ-1030 The American Journal of Human Genetics 101, 1021–1033, Decuals is similar to that of individuals with ACTB deletions
as opposed to BRWS [MIM: 243310],22 which suggests
that the dosage of full-length b-actin plays an important
role in normal human development.ember 7, 2017
All individuals in our cohort displayed developmental
delay and apparent intellectual disability. In several indi-
viduals, expressive speech was severely affected. A trusting,
empathetic, or sociable personality was reported indepen-
dently in many individuals. Some were reported to have
autism-spectrum or attention-deficit hyperactivity disor-
ders. Actin filaments are a major structural component of
synapses and are critical for synaptic plasticity, which
directly influences neurodevelopment, cognitive perfor-
mance, and social behavior.23,24 This could explain the
developmental and behavioral phenotype of affected
individuals.
Among ten individuals whowere investigated with brain
magnetic-resonance imaging, eight (80%) were detected to
have some abnormality, including gray-matter heteroto-
pias in two individuals (Table 1). This is consistent with
neuronal migration defects, prominent expression of
b-actin in cortical neurons of developing mice, and our
findings of defects in cellular migration in cells from
affected individuals. Other neuroradiological features
included cortical atrophy, cerebral white-matter hyperin-
tensities, a thin corpus callosum, a septum pellucidum
cyst, megacisterna magna, ventricular enlargement, and
hydrocephalus. Seizures were reported in a minor subset
of individuals, and one individual had dystonia. Delayed-
onset generalized dystonia has been reported in monozy-
gotic twins with an ACTB p.Arg183Trp mutation.25
Congenital cardiac anomalies such as ventricular and
atrial septal defects, sub-aortic stenosis, tortuous arch, total
anomalous pulmonary venous drainage, patent ductus
arteriosus, tricuspid valve dysplasia, and ventricular dilata-
tion were observed in 11 out of 22 (50%) individuals who
were investigated by echocardiogram or post-mortem ex-
amination (Table 1). Major renal anomalies were detected
in 7 out of 19 (36.8%) individuals whose renal ultrasound
examination or post-mortem reports were available. These
included four individuals with horseshoe kidneys, and one
each with unilateral renal agenesis, pelvic kidney, and kid-
ney cysts (Table 1). Vesicouretric reflux and hydronephro-
sis were also seen in some individuals. Those males, who
lacked overt renal malformations, still had a high fre-
quency of anomalies such as inguinal hernias, hypospa-
dias, micropenis, urethral cyst and cryptorchidism. Spinal
and palatal anomalies were also detected in six and four
individuals, respectively. Collectively, our data show that
internal organ malformations, particularly in the heart
and kidneys, are much more frequent in individuals with
loss-of-function ACTB mutations than in the general pop-
ulation.26–29 A role of b-actin in morphogenesis is sup-
ported by our detection of this protein in the developing
heart and kidney epithelia in mice. Furthermore, in cells
from affected individuals, we showed altered cellular
morphology, migration, and proliferation, which are all
key developmental processes.
Although growth parameters were not available for all
affected individuals, we noted growth retardation in 13 in-
dividuals. This could be related to b-actin’s role in cellThe American Jourgrowth and proliferation, which we also observed in the
affected individual’s cells.17
The individuals described here have overlapping dys-
morphism with interrupted wavy eyebrows, dense eye-
lashes, hypertelorism, a wide nose, a wide mouth, and a
prominent chin. This is distinct from the typical facial dys-
morphism of BRWS, although we did notice some overlap-
ping features, such as a wide mouth and hypertelorism,
in both groups. None of our individuals were detected to
have agyria/pachygyria or coloboma, which are frequent
in BRWS.30,31 This further emphasizes that ACTB loss-of-
function mutations cause a specific syndrome distinct
from BRWS.
The facial characteristics of individual described here
resemble those in several chromatin remodeling disorders,
such as the interrupted eyebrows in Kabuki syndrome
[MIM: 147920 and 300867]32,33 and the typical lip config-
uration and large mouth seen in KBG syndrome [MIM:
148050]. b-actin is a part of chromatin remodeling com-
plexes such as SWR1 and SWI-SNF,18 and mutations in
its components cause Floating-Harbour syndrome [MIM:
136140]34 and Coffin-Siris syndrome [MIM: 135900],35
respectively. Of note, we detected decreased amounts of
nuclear b-actin, along with dysregulated gene expression,
in cells of affected individuals. The role of nuclear b-actin
has been the subject of recent intense research,36,37 and
our results highlight the importance of its correct dosage
in human development.
In summary, we have described, in 33 individuals,
a pleiotropic disorder caused by haploinsufficiency of
ACTB, which encodes for the most abundant eukaryotic
cytoplasmic protein, b-actin. Although we have shown
some of the consequences of reduced dosage of ACTB
in vitro, further studies will be required to if we are to
understand the mechanisms behind the phenotypes re-
sulting from loss-of-function ACTB mutations. Notably,
the mechanisms linking ACTB missense mutations with
BRWS also remain unknown. The partial overlap of pheno-
types of individuals with BRWS and ACTB loss-of-function
mutations suggest that perhaps the underlying mecha-
nism of BRWS is not just, as postulated, gain of function,
but might also include some effects resulting from loss-
of-function or dominant-negative effects. Researchers are
increasingly recognizing that different mutations in the
same gene can have different underlying genetic effects
and thus can result in different phenotypes.38 Interest-
ingly, missense ACTG1 [MIM: 102560] (encoding the
only other ubiquitously expressed actin, g-actin) muta-
tions also result in BRWS.22 However, we did not observe
any distinct phenotype that could be attributed to
ACTG1 deletions (data not presented). Of note, the pLI
score for ACTG1 is 0.22, which decreases the likelihood
that heterozygous loss-of-function mutations in this gene
are a cause of an early-onset human disorder. Hence, these
observations support overlapping but distinct cellular roles
for the two ubiquitously expressed b- and g-actins. Overall,
our linked biology studies suggest that a critically reducednal of Human Genetics 101, 1021–1033, December 7, 2017 1031
amount of b-actin alters cell shape, migration, prolifera-
tion, and gene expression to the detriment of brain, heart,
and kidney development.Supplemental Data
Supplemental data include three figures and three tables and can
be found with this article online at https://doi.org/10.1016/j.
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Figure S1: Analysis of fibroblast morphology without being treated with siRNA constructs. (A) 
Immunostaining of fibroblast cells stained for Phalloidin expression and DAPI (Scale bar: 50 µm; Ctrl 
F1: control fibroblast, P1: sample from IVa in Table 1). (B) Bar chart shows the cell area (µm
2
) of 
control or affected individual fibroblast cells transfected with ACTB siRNA or control siRNA. 
Measurement has been done using ImageJ software. (C) Bar chart shows the circularity of control or 
affected individual fibroblast cells transfected with ACTB siRNA or control siRNA. Measurement has 
been done using ImageJ software (n=4; ** P<0.01). Circularity with a value of 1 indicates a perfect 
circle. As the value approaches 0, it indicates an increasingly elongated shape. 
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Figure S2: Cell transfection protocol and confirmation of ACTB knockdown. (A) Scheme of the 
protocol used to down-regulate ACTB with siRNA. Cells were transduced with 10nM siRNA constructs 
at -48h, -24h and 0h. Seventy-two and ninety-six hours later, cells were analysed by qRT-PCR, 
western blot and other down-stream assays. (B) Quantitative RT-PCR analysis of ACTB transcript 
level relative to GAPDH in fibroblasts samples transfected with siRNA against ACTB or control (Ctrl 
F1: control fibroblast, P1: sample from IVa). 
 
 
 
 
 
 
 
 
 
 
0
0.5
1
1.5
2
2.5
3
3.5
4
Ctrl F1 Ctrl
siRNA
Ctrl F1 ACTB
siRNA
Ctrl F1 Ctrl
siRNA
Ctrl F1 ACTB
siRNA
P1 Ctrl siRNA P1 Ctrl siRNA
72h 96h 72h 96h
E
x
p
re
s
s
io
n
 l
e
v
e
l 
re
la
ti
v
e
 t
o
 G
A
P
D
H
 
ACTB 
 
 -48h -24h 0h 
siRNA transfection 10nM 
72h 96h 
Proliferation assay 
qRT-PCR 
Western blot 
Migration assay 
Immunostaining 
Ctrl siRNA  
ACTB siRNA  
Fibroblast cells 
A 
B 
 SUPPLEMENTARY TABLES 
 
 
Family Origin Decipher ID Deletion coordinates (Hg19) Size (Mb) 
Discovery Cohort 
I UK 271006 7:5151574-6745570 1.59 
II UK 256348 7: 5370613-6296827 0.93 
III UK 258437 7: 5057992- 5617869 0.56 
IV UK 255897 7: 5587489-6080286 0.49 
Validation Cohort 
V Canada 998 7: 3531608-7167693 3.64 
VI Austria 284613 7: 5592436-8416721 2.82 
VII Italy 254233 7: 3861164-6213355 2.35 
VIII Italy 256546 7: 3861164-5864755 2.00 
IX Spain - 7: 5105131-6714753 1.61 
X France 268591 7: 5399371-6871084 1.47 
XI Belgum 253773 7: 5370746-6781213 1.41 
XII UK 252339 7: 4778156-5945860 1.17 
XIII Australia - 7: 5184455-6348344 1.16 
XIV Australia 274371 7: 5151474-6296948 1.15 
XV Belgium 289362 7: 5048743-6146825 1.10 
XVI UK 272915 7: 4861557-5923456 1.06 
XVII Belgium 288265 7: 5233021-5926631 0.69 
XVIII UK 301216 7: 5370613-5925070 0.55 
XIX UK 259191 7: 5241760-5675100 0.43 
XX France 264408 7: 5492967-5864851 0.37 
XXI UK 283142 7: 5548368-5857259 0.31 
XXII Australia - 7: 5359680-5568627 0.21 
XXIII France - 7: 5536848-5617875 0.08 
Intragenic variants 
XXIV UK 263884 7: 5567409-5567409; c.1097dupG; 
p.(Ser368LeufsTer13) 
XXV UK 267004 7: 5567390; c.1117A>T; p.(Lys373Ter) 
XXVI Canada - NM_001101:exon3: c.329delT; 
p.(Leu110ArgfsTer10) 
 
Table S1: Genotypes of individuals described in this study. 
 
  
  
Gene Probability of Loss-of-
function intolerance (pLI) 
Residual Variation 
Intolerance score p0.1% 
(percentile)  
haploinsufficiency 
index (HI index %) 
ACTB 0.94 -0.67 (16) 1.03 
AIMP2 0.00 -0.36 (29) 41.23 
ANKRD61 NA NA 85.91 
C7orf26 0.83 -0.34 (31) 56.53 
CCZ1 0.99 -0.16 (42) 39.44 
CYTH3 0.36 -0.54 (20) 50.20 
DAGLB 0.00 0.03 (56) 71.98 
EIF2AK1 0.00 0.36 (75) 66.82 
FAM220A 0.00 0.89 (89) 96.17 
FBXL18 0.00 -0.80 (12) 62.82 
FSCN1 0.78 -0.04 (50) 21.98 
GRID2IP 0.31 NA 61.05 
KDELR2 0.27 -0.38 (27) 26.59 
OCM 0.00 0.44 (78) 46.73 
PMS2 0.00 1.48 (95) 59.43 
RAC1 0.57 -0.16 (41) 0.72 
RBAK 0.01 0 (54) 79.68 
RNF216 0.41 -1.19 (6) 36.49 
RSPH10B NA NA 86.61 
SLC29A4 0.00 -0.99 (9) 66.44 
TNRC18 1.00 NA 61.51 
USP42 1.00 0.52 (80) 78.60 
IPI2 0.09 0.13 (63) 47.26 
ZDHHC4 0.00 0.78 (87) 79.09 
ZNF12 0.55 -0.2 (39) 73.57 
ZNF316 NA NA NA 
ZNF853 0.00 NA 84.37 
 
Table S2: Scores for intolerance of loss of function and haploinsufficiency for protein coding 
genes located on human chromosome 7p22.1. 
We compiled the LoF intolerance (pLI) score
1
 from http://exac.broadinstitute.org/; Residual Variation 
Intolerance score (RVIS)
2
 from http://genic-intolerance.org/ and haploinsufficiency index (HI)
3
 from 
DECIPHER. All resources were accessed on 03/04/2017 (NA, Data not available; pLi>0.9; RVIS 
percentile of <20; and HI of <20 are highlighted in bold). 
  
  
  
Gene 
name 
Aggregate FPKM values 
 P2 P4 MeanP C1 C2 MeanC MeanP/ 
MeanC 
G1-phase 
CCND1 3.9 8.0 6.0 0.5 0.6 0.5 11.1 
S-phase 
ABL1 18.6 24.7 21.7 19.7 14.7 17.2 1.3 
CDC6 4.1 15.0 9.5 23.0 10.8 16.9 0.6 
MCM2 42.8 71.1 57.0 110.2 68.1 89.1 0.6 
MCM3 32.8 57.1 45.0 87.5 77.7 82.6 0.5 
MCM4 16.6 51.0 33.8 81.4 42.3 61.9 0.5 
MCM5 57.6 76.5 67.1 166.0 142.6 154.3 0.4 
WEE1 11.0 21.3 16.2 18.9 13.8 16.4 1.0 
G2-phase 
ANAPC2 14.2 19.9 17.0 30 21.7 25.9 0.7 
BCCIP 52.2 64.8 58.5 73.4 57.1 65.2 0.9 
BIRC5 16.5 31.3 23.9 56.7 44.1 50.4 0.5 
CCNB1 22.3 52.5 37.4 81.0 59.0 70.0 0.5 
CDK5RAP1 14.0 12.5 13.3 17.6 57.6 37.6 0.4 
CDKN3 23.7 23.7 23.7 59.7 70.7 65.2 0.4 
CKS1B 8.6 8.6 8.6 16.4 19.9 18.1 0.5 
CKS2 47.4 80.1 63.8 162.0 195.3 178.7 0.4 
GTSE1 7.4 15.1 11.3 26.8 33.2 30.0 0.4 
KPNA2 59.5 124.5 92.0 145.4 103.3 124.4 0.7 
MNAT1 35.0 54.6 44.8 77.8 78.7 78.2 0.6 
 
Table S3: Comparison of aggregate FPKM values in control and affected individual LCLs for 
genes expressed in G1, S and G2 phases of the cell cycle.  
P2 is from XI, P4 is from XXII in Table 1 (FPKM, Fragments Per Kilobase of transcript per Million 
mapped reads).  
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